← Browse by Condition
Medical Condition
adjuvant chemotherapy
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 3
NCT07136077 Phase 2
Recruiting
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Enrollment
20 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07366528 Phase 3
Recruiting
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Enrollment
387 pts
Location
China
Sponsor
Ruijin Hospital